Disease · MONDO_0005159

prostate carcinoma

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. prostate carcinoma. Diseases, record MONDO_0005159. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005159

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: prostate carcinoma; Open Targets
Open Targets ID: MONDO_0005159; Open Targets
Other names: carcinoma of prostate, carcinoma of prostate gland, carcinoma of the prostate, prostate gland carcinoma; Open Targets
Disease Ontology: DOID:10286; Disease Ontology
NCI Thesaurus: C4863; NCI Thesaurus
Highest stage of its drugs: Approval, for 13 of its 44 drugs, from DailyMed and FDA; Open Targets

Drugs44

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
LEUPROLIDE ACETATE	CHEMBL1200775	Protein	Approval	DailyMed	9	2	2	Drugs and targets
FLUTAMIDE	CHEMBL806	Small molecule	Approval	DailyMed	4	2	2	Drugs and targets
ZOLEDRONIC ACID	CHEMBL4303669	Small molecule	Approval	DailyMed	20	1	1	Drugs and targets
ABIRATERONE ACETATE	CHEMBL271227	Small molecule	Approval	DailyMed	2	1	1	Drugs and targets
FINASTERIDE	CHEMBL710	Small molecule	Approval	DailyMed	24	0	0	Drugs and targets
DUTASTERIDE	CHEMBL1200969	Small molecule	Approval	DailyMed	5	0	0	Drugs and targets
TAMSULOSIN HYDROCHLORIDE	CHEMBL1200914	Small molecule	Approval	DailyMed	2	0	0	Drugs and targets
APALUTAMIDE	CHEMBL3183409	Small molecule	Approval	FDA	1	0	0	Drugs and targets
DEGARELIX ACETATE	CHEMBL2028987	Protein	Approval	DailyMed	1	0	0	Drugs and targets
ENZALUTAMIDE	CHEMBL1082407	Small molecule	Approval	DailyMed	1	0	0	Drugs and targets

1 to 10 of 44

See all 44 drugs

Targets103

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
GNRHR	Gonadotropin-releasing hormone receptor	7	Gonadotropin-releasing hormone receptor agonist; Gonadotropin-releasing hormone receptor antagonist	Approval	https://conductscience.org/library/genes/2798	Drugs and targets
AR	Androgen receptor	4	Androgen Receptor antagonist	Approval	https://conductscience.org/library/genes/367	Drugs and targets
TUBA1A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7846	Drugs and targets
TUBA1B	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/10376	Drugs and targets
TUBA1C	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/84790	Drugs and targets
TUBA3C	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7278	Drugs and targets
TUBA3E	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/112714	Drugs and targets
TUBA4A	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/7277	Drugs and targets
TUBB	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/203068	Drugs and targets
TUBB1	Tubulin	4	Tubulin inhibitor	Phase 2	https://conductscience.org/library/genes/81027	Drugs and targets

1 to 10 of 103

See all 103 targets

Trials27

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT02234115	Safety, Efficacy, and Pharmacokinetic Behavior of Leuprolide Mesylate in Subjects With Advanced Prostate Carcinoma	Phase 3	137	2018-04-13	Prostatic Neoplasms	LEUPROLIDE	Its record names the disease	ClinicalTrials.gov
NCT00147212	ET 743 (Yondelis) in Men With Advanced Prostate Cancer	Phase 2	50	2013-01-18	Prostate Cancer	TRABECTEDIN	Its record names the disease	ClinicalTrials.gov
NCT02712320	Open-Label Safety Extension Study in Patients Who Have Previously Participated and Have Benefited From LMIS 50 mg	Phase 3	30	2018-09-12	Prostatic Neoplasms	LEUPROLIDE MESYLATE	Its record names the disease	ClinicalTrials.gov
NCT00193856	RADAR Trial - Randomised Androgen Deprivation and Radiotherapy	Phase 3	1,071		Prostate Cancer	LEUPROLIDE ACETATE, ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT02128334	An Observational Study Looking at How Well the Drug Eligard Works and How Well it is Tolerated by the Body of Patients With Advanced Prostate Carcinoma in the Russian Federation		645		Advanced Prostate Carcinoma	LEUPROLIDE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT02484339	Treatment of Advanced Castration Resistant Prostate Carcinoma With Limited Bone Metastases (α-RT)	Phase 2	274		Prostate Carcinoma	RADIUM RA 223 DICHLORIDE	Its record names the disease	ClinicalTrials.gov
NCT00919022	Androcur Non-interventional Study Among Patients With Carcinoma of the Prostate		194		Prostate Cancer	CYPROTERONE ACETATE	Its record names the disease	ClinicalTrials.gov
NCT00031187	Study of SGN-15, Antibody-Drug Conjugate, to Treat Hormone Refractory Prostate Cancer	Phase 2	160		Prostatic Neoplasms	DOCETAXEL, SGN-15	Its record names the disease	ClinicalTrials.gov
NCT00182052	Rosiglitazone (Avandia) vs. Placebo for Androgen Dependent Prostate Cancer	Phase 3	100		Adenocarcinoma of the Prostate, Prostate Cancer	ROSIGLITAZONE	Its record names the disease	ClinicalTrials.gov
NCT00193193	Weekly Paclitaxel, Low-Dose Estramustine, and Carboplatin in the Treatment of Hormone Refractory Prostate Carcinoma	Phase 2	100		Prostate Cancer	CARBOPLATIN, ESTRAMUSTINE, PACLITAXEL	Its record names the disease	ClinicalTrials.gov

1 to 10 of 27

See all 27 trials

Comparisons in its trials0

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

None in this release.

Papers from its trials30

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
19706804	RESULT	1	PubMed
19470936	RESULT	1	PubMed
19211454	RESULT	1	PubMed
19017549	RESULT	1	PubMed
18779620	RESULT	1	PubMed
18413638	RESULT	1	PubMed
18243498	RESULT	1	PubMed
17881290	RESULT	1	PubMed
17689883	RESULT	1	PubMed
17634487	RESULT	1	PubMed

1 to 10 of 30

See all 30 papers from its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005159

GET https://conductscience.org/api/diseases/v1/MONDO_0005159/drugs?page=2

API reference For AI assistants